Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1 1

Status

Completed 5

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 5Breast 4Other hematologic neoplasm 3Lymphoid 3Plasma cell 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Dermatologic 1CNS 1

Conditions

Neoplasms 5

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Palonosetron × Tumor-Agnostic × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT01836705 2025-03-05

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

NCT03097588 2021-07-12

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

OHSU Knight Cancer Institute

Phase 2 Completed
43 enrolled 18 charts
Tumor-Agnostic

Neoplasms

NCT01909856 2015-12-04

The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Completed
92 enrolled
Tumor-Agnostic

Neoplasms

NCT01640340 2013-11-07

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Ohio State University Comprehensive Cancer Center

Phase NA Completed
40 enrolled 12 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡